Eli Lilly CDR (CAD Hedged)

The FDA issued warning letters to Eli Lilly, Novo Nordisk, and Hims & Hers Health on September 9, 2025, for misleading advertising of weight-loss medications including Mounjaro, Zepbound, Ozempic, and Wegovy.

Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.

Eli Lilly announces plans to build a $5 billion manufacturing facility in Virginia's Goochland County, marking the company's first dedicated bioconjugate platform and monoclonal antibody production site.

Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.

CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.

Takeda has appointed Rhonda Pacheco, former group vice president of U.S. Cardiometabolic Health at Eli Lilly, as president of its U.S. Business Unit effective September 29, 2025.

The Institute for Clinical and Economic Review has reversed its 2022 assessment, now finding GLP-1 drugs from Novo Nordisk and Eli Lilly cost-effective for obesity treatment with substantial health benefits beyond weight loss.

UNC Lineberger Comprehensive Cancer Center launches hybrid decentralized trials with $250,000 federal funding to serve North Carolina's 33% rural population, reducing travel barriers to Chapel Hill.

insitro and Eli Lilly announced a collaboration to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.

Eli Lilly has launched TuneLab, an AI/ML platform providing biotech companies access to drug discovery models trained on over $1 billion worth of proprietary research data.